Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial

•The 4-day fractionated regimen allows significantly more patients to receive a third cycle of cisplatin, with fewer dose reductions than the standard regimen concurrently with radiotherapy.•Toxicity is remarkably reduced with the 4-day regimen compared to a standard cisplatin administration.•The ti...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2024-08, Vol.197, p.110329-110329, Article 110329
Main Authors: Borel, Christian, Sun, Xu-Shan, Coutte, Alexandre, Bera, Guillaume, Sire, Christian, Zanetta, Sylvie, Alfonsi, Marc, Janoray, Guillaume, Chatellier, Thierry, Garcia-Ramirez, Muriel, Gherga, Elisabeta, Hammoud, Yasser, Burgy, Mickaël, Etienne-Selloum, Nelly, Pechery, Adeline, Girard-Calais, Marie-Hélène, Velten, Michel, Pignon, Jean-Pierre, Wanneveich, Mathilde, Bourhis, Jean
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - therapeutic use
Cancer
Chemoradiotherapy
Chemoradiotherapy - methods
Cisplatin
Cisplatin - administration & dosage
Cisplatin pharmacokinetic
Dose Fractionation, Radiation
Female
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - radiotherapy
Head and Neck Neoplasms - therapy
Hematology, Oncology, and Palliative Medicine
Human health and pathology
Humans
Life Sciences
Locally advanced
Male
Middle Aged
Squamous Cell Carcinoma of Head and Neck
Squamous Cell Carcinoma of Head and Neck - drug therapy
Squamous Cell Carcinoma of Head and Neck - pathology
Squamous Cell Carcinoma of Head and Neck - radiotherapy
Squamous Cell Carcinoma of Head and Neck - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!